MedTrace Logo

Trial of Dasatinib in Advanced Sarcomas

NCT00464620 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 366

Last updated 2018-11-23

Study results available
· View outcomes & findings →

Summary

This study will examine the response rate and the 6-month progression-free survival rates of subjects with advanced sarcoma treated with dasatinib.

Conditions

  • Rhabdomyosarcoma
  • Malignant Peripheral Nerve Sheath Tumors
  • Chondrosarcoma
  • Sarcoma, Ewing's
  • Sarcoma, Alveolar Soft Part
  • Chordoma
  • Epithelioid Sarcoma
  • Giant Cell Tumor of Bone
  • Hemangiopericytoma
  • Gastrointestinal Stromal Tumor (GIST)

Interventions

DRUG

Dasatinib

oral agent, continuous dosing, Cycles = 28 days

Sponsors & Collaborators

  • Bristol-Myers Squibb

    collaborator INDUSTRY

  • Sarcoma Alliance for Research through Collaboration

    lead OTHER

Principal Investigators

  • Scott Schuetze, MD, PhD · University of Michigan

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2016-12-31
Completion
2017-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00464620 on ClinicalTrials.gov